EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

PO033 | PLATELET COUNT AND PERIPROCEDURAL MAJOR BLEEDING IN CIRRHOTIC PATIENTS UNDERGOING INVASIVE PROCEDURES: INDIVIDUAL PATIENT DATA META-ANALYSIS

Elisa Tarasconi

Bleeding, Thrombosis and Vascular Biology · 26.10.2026 · 5 (s3)

DOI: 10.4081/btvb.2026.849 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 26.10.2026. Verfasst von Elisa Tarasconi. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims. Cirrhotic patients have a fragile hemostatic balance, which can be perturbed by invasive procedures. Thrombocytopenia is often feared because of the risk of periprocedural bleeding and some guidelines recommend platelet transfusion for counts below 50x109/L. However, evidence supporting this practice remains conflicting. We performed an individual patient data meta-analysis to evaluate the impact of the platelet count on periprocedural bleeding in cirrhotic patients undergoing invasive procedures.

Methods

We searched Medline and Embase for randomized controlled trials and prospective and cohort studies published between 2010 and 2021 using a pre-defined research string. We included studies in English reporting on periprocedural major bleeding (ISTH definition) and post-procedural mortality in adult patients with cirrhosis undergoing laparotomic, laparoscopic or percutaneous procedures. Patients undergoing endoscopic or endovascular procedures and those receiving thrombopoietin receptor agonists were excluded. Eligible procedures were classified as high- or low-bleeding risk according to predefined criteria. Individual patient data (including platelet counts) were requested from study authors. The primary outcome of this study was the prevalence of periprocedural major bleeding.

Results

Of 585 retrieved citations, we included 9 studies, resulting in 2747 cirrhotic patients who underwent a total of 3136 eligible procedures. Eligible patients were stratified based on their platelet counts: less than 50x109/L (n=394), 50 to 99x109/L (n=969), and 100x109/L or more (n=1384). Of the eligible procedures, 2135 (68%) were classified at high bleeding risk. Overall, the prevalence of periprocedural major bleeding was 8% (243/3136). Stratifying patients by platelet count, the prevalence of periprocedural major bleeding was 8% (34/416) in patients with counts

Zitieren

APA

Tarasconi, E. (2026). PO033 | PLATELET COUNT AND PERIPROCEDURAL MAJOR BLEEDING IN CIRRHOTIC PATIENTS UNDERGOING INVASIVE PROCEDURES: INDIVIDUAL PATIENT DATA META-ANALYSIS. Bleeding, Thrombosis and Vascular Biology, 5(s3). https://doi.org/10.4081/btvb.2026.849

Vancouver

Tarasconi E. PO033 | PLATELET COUNT AND PERIPROCEDURAL MAJOR BLEEDING IN CIRRHOTIC PATIENTS UNDERGOING INVASIVE PROCEDURES: INDIVIDUAL PATIENT DATA META-ANALYSIS. Bleeding, Thrombosis and Vascular Biology. 2026;5(s3). doi:10.4081/btvb.2026.849

BibTeX
@article{Tarasconi2026,
  author = {Tarasconi, Elisa},
  title = {PO033 | PLATELET COUNT AND PERIPROCEDURAL MAJOR BLEEDING IN CIRRHOTIC PATIENTS UNDERGOING INVASIVE PROCEDURES: INDIVIDUAL PATIENT DATA META-ANALYSIS},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  volume = {5},
  number = {s3},
  doi = {10.4081/btvb.2026.849}
}
Kostenlos starten →